# Nuclide record anbl1531 (trial). Data CC BY-NC 4.0, attribute "Data from Nuclide (nuclide.cc)". Whole corpus: https://nuclide.cc/api/v1/nuclide.nt
@prefix schema: <https://schema.org/> .
@prefix nuclide: <https://nuclide.cc/ns#> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .

<https://nuclide.cc/trials/anbl1531/>
  a schema:MedicalTrial ;
  nuclide:kind "trial" ;
  schema:identifier "anbl1531", "NCT03126916" ;
  schema:name "COG ANBL1531"@en ;
  schema:description "COG ANBL1531 is the current North American high-risk trial, adding targeted radiation during induction and an ALK pill for children whose tumours carry ALK mutations."@en ;
  schema:url <https://nuclide.cc/trials/anbl1531/> ;
  schema:dateModified "2026-09-07"^^xsd:date ;
  schema:citation <https://clinicaltrials.gov/study/NCT03126916> ;
  nuclide:status "active" ;
  nuclide:phase "3" ;
  nuclide:related <https://nuclide.cc/isotopes/i-131/> ;
  nuclide:indications <https://nuclide.cc/indications/neuroblastoma/>, <https://nuclide.cc/indications/neuroblastoma-high-risk/> ;
  nuclide:technologies <https://nuclide.cc/technologies/mibg-theranostics/> ;
  nuclide:drugs <https://nuclide.cc/drugs/i131-mibg/> .